Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2022 pubmed 7 citations

Evaluation of circulating serum cathelicidin levels as a potential biomarker to discriminate between active and latent tuberculosis in Uganda.

Acen. Ester Lilian EL; Kateete. David Patrick DP; Worodria. William W; Olum. Ronald R; Joloba. Moses L ML; Bbuye. Mudarshiru M; Biraro. Irene Andia IA

Key Findings

  • Active TB patients showed significantly higher serum LL‑37 levels than latent TB and TB‑free individuals
  • Males had higher LL‑37 levels than females in the study
  • LL‑37 could modestly discriminate active TB from no TB (AUC 0.71) but performed poorly for latent TB (AUC 0.55)

Practical Outcomes

  • For biohackers, LL‑37 isn’t a direct tool for boosting longevity or performance, but knowing it spikes during active TB could be useful for early infection monitoring. It suggests that measuring LL‑37 might help flag active TB, though more validation is needed before it becomes a reliable DIY health test.

Summary

The study found that people with active tuberculosis have higher levels of the natural immune peptide LL‑37 in their blood compared to those with latent infection or no infection, and that this difference can help tell the disease states apart, especially distinguishing active TB from no TB.

Abstract

Tuberculosis remains a major public health problem worldwide accounting for 1.4 million deaths annually. LL-37 is an effector molecule involved in immunity with both antimicrobial and immunomodulatory properties. The purpose of this study was to compare LL-37 circulatory levels among participants with active and latent tuberculosis and to determine its ability to discriminate between the two infectious states. A cross-sectional study was performed among 56 active tuberculosis patients, 49 latent tuberculosis individuals, and 43 individuals without tuberculosis infection. The enzyme-linked immunosorbent assay was used to assess LL-37 levels. Data analysis was performed using STATA software and Graph pad Prism version 8. Mann-Whitney U test was used for correlation between variables with two categories and the Kruskal-Wallis test for three or more categories. The study had more female participants than males, with similar median ages across the three groups, 29.5, 25.0, and 23.0 years respectively. Active tuberculosis patients had significantly higher LL-37 levels compared to those with latent tuberculosis and without tuberculosis. The median/interquartile ranges were 318.8 ng/ml (157.9-547.1), 242.2 ng/ml (136.2-579.3), 170.9 ng/ml (129.3-228.3); p = 0.002 respectively. Higher LL-37 was found in the male participant with median/interquartile range, 424.8 ng/ml (226.2-666.8) compared to the females 237.7 ng/ml (129.6-466.6); p = 0.045. LL-37 had better discriminatory potential between active tuberculosis and no tuberculosis (AUC = 0.71, sensitivity 71.4% specificity = 69.8%) than with latent tuberculosis (AUC = 0.55, sensitivity = 71.4%, specificity = 44.9%). There was moderate differentiation between latent tuberculosis and no tuberculosis (AUC = 0.63, sensitivity = 44.9% specificity = 90.7%). Significantly higher LL-37 levels were observed among active tuberculosis patients than those without tuberculosis infection and were, therefore able to discriminate between active tuberculosis and other tuberculosis infectious states, especially with no tuberculosis. Further assessment of this biomarker as a screening tool to exclude tuberculosis is required.

Study Information

Provider

pubmed

Year

2022

Date

2022-08-26T00:00:00.000Z

DOI

10.1371/journal.pone.0272788

Citations

7

References

54